+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Anaplastic Astrocytoma Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767475
  • Report
  • April 2019
  • Region: Global
  • 158 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Insys Therapeutics Inc
  • Merck & Co Inc
  • MORE
The global clinical trial report- “2019 Anaplastic Astrocytoma Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Anaplastic Astrocytoma. It presents in-depth analysis of Anaplastic Astrocytoma clinical trials across markets and companies. The research work is for providing complete understanding into trends in Anaplastic Astrocytoma.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Anaplastic Astrocytoma clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Anaplastic Astrocytoma

The research work is prepared through extensive and continuous research on Anaplastic Astrocytoma trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Anaplastic Astrocytoma patients are identified
  • The report includes panorama of Anaplastic Astrocytoma clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Anaplastic Astrocytoma clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Insys Therapeutics Inc
  • Merck & Co Inc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Anaplastic Astrocytoma Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Anaplastic Astrocytoma Clinical Trials by Region
2.2.2 Average Enrollment of Anaplastic Astrocytoma Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Anaplastic Astrocytoma Treatment, 2019

3. Region wise Anaplastic Astrocytoma Clinical Trials
3.1 Asia Pacific Anaplastic Astrocytoma Clinical Trials by Country
3.2 Europe Anaplastic Astrocytoma Clinical Trials by Country
3.3 North America Anaplastic Astrocytoma Clinical Trials by Country
3.4 Middle East and Africa Anaplastic Astrocytoma Clinical Trials by Country
3.5 South and Central America Anaplastic Astrocytoma Clinical Trials by Country

4. Anaplastic Astrocytoma Clinical Trial Trends
4.1 Start Year wise Anaplastic Astrocytoma Clinical Trials
4.2 Phase wise Anaplastic Astrocytoma Clinical Trials
4.3 Trial Status wise Anaplastic Astrocytoma Clinical Trials
4.4 Trial Type wise Anaplastic Astrocytoma Clinical Trials

5. Anaplastic Astrocytoma Average Enrollment Trends
5.1 Average Enrollment in Anaplastic Astrocytoma Trials by Year
5.2 Average Enrollment in Anaplastic Astrocytoma Trials by Phase
5.3 Average Enrollment in Anaplastic Astrocytoma Trials by Status
5.4 Average Enrollment in Anaplastic Astrocytoma Trials by Type of Trial

6. Companies Participating in Anaplastic Astrocytoma Clinical Trials
6.1 Anaplastic Astrocytoma Trials by Sponsor Type
6.2 Anaplastic Astrocytoma Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Anaplastic Astrocytoma Trials- Phase 1
7.2 Anaplastic Astrocytoma Trials- Phase 2
7.3 Anaplastic Astrocytoma Trials- Phase 3
7.4 Anaplastic Astrocytoma Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Anaplastic Astrocytoma Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Figure 5: Europe - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Figure 7: North America - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Figure 9: Anaplastic Astrocytoma Clinical Trials by Phase
Figure 10: Anaplastic Astrocytoma Clinical Trials by Trial Status
Figure 11: Anaplastic Astrocytoma Clinical Trials by Type
Figure 12: Anaplastic Astrocytoma Clinical Trials by Sponsor Type
Figure 13: Anaplastic Astrocytoma Clinical Trials by Leading Sponsors
Figure 14: Anaplastic Astrocytoma Average Enrollment by Phase
Figure 15: Anaplastic Astrocytoma Average Enrollment by Trial Status
Figure 16: Anaplastic Astrocytoma Average Enrollment by Type
Figure 17: Anaplastic Astrocytoma- Average Enrolment by Type of Sponsors
Figure 18: Anaplastic Astrocytoma- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Anaplastic Astrocytoma Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Table 5: Europe - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Table 7: North America - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Anaplastic Astrocytoma Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Anaplastic Astrocytoma Average Enrollment by Phase
Table 15: Anaplastic Astrocytoma Average Enrollment by Trial Status
Table 16: Anaplastic Astrocytoma Average Enrollment by Type
Table 17: Anaplastic Astrocytoma- Average Enrolment by Type of Sponsors
Table 18: Anaplastic Astrocytoma- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Burzynski Research Institute Inc
  • C. H. Boehringer Sohn AG & Co KG
  • Celgene Corp
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Insys Therapeutics Inc
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll